{
    "clinical_study": {
        "@rank": "134485", 
        "arm_group": [
            {
                "arm_group_label": "MOD-4023", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter\n      study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once\n      weekly injection of modified hGH (MOD-4023)."
        }, 
        "brief_title": "A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Adult Growth Hormone Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women between the age of 23 to 70 years old at screening, inclusive\n\n          -  GHD subjects as defined in the Consensus guidelines for the diagnosis and treatment\n             of adults with GH deficiency II (2007).\n\n          -  No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with\n             any registered or investigational r-hGH or GH secretagogue product.\n\n          -  The IGF-I level at screening \u2264-1 SDS of the age and sex normal ranges according to\n             the central laboratory measurements\n\n          -  Subjects who are on a stable diet and exercise regime and do not have plans to modify\n             their diet or exercise for at least 12 months\n\n          -  Subject had a DXA screening and the results are interpretable according to the study\n             plan.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or breast-feeding (at least 6 months delay from childbirth or\n             lactation)\n\n          -  Evidence of growth benign intracranial tumor within the last 12 months (determined by\n             comparing a previous MRI to a new one obtained no more than 6 months prior to study\n             entry to clarify dynamics of growth).\n\n          -  History of any cancer. Exceptions to this exclusion criterion include resected in\n             situ carcinoma  of the cervix and squamous cell or basal cell carcinoma of the skin\n             with complete local excision. Patients with GHD attributed to treatment of\n             intracranial malignant lesions in childhood or adulthood (or, tumors) or leukemia may\n             also be enrolled into the study provided that a recurrence-free survival period of at\n             least 5 years is well documented in the study record.\n\n          -  Signs of intracranial hypertension at screening\n\n          -  Heart insufficiency, NYHA class > 2 (Appendix B)\n\n          -  History of overt diabetes mellitus (including currently treated, well-controlled DM)\n             defined according to the American Diabetes Association (ADA) Criteriaa. A history of\n             gestational diabetes, resolved after childbirth, is not exclusionary.\n\n          -  History of Acromegaly"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "23 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909479", 
            "org_study_id": "CP-4-005", 
            "secondary_id": "2013-000830-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "MOD-4023", 
                "description": "Individualized once weekly dose of MOD-4023", 
                "intervention_name": "MOD-4023", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Once weekly administration of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "contact": {
                "email": "kspiller@aghendo.com", 
                "last_name": "Kellie Spiller, MS", 
                "phone": "412-359-5143"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15212"
                }, 
                "name": "Allegheny Endocrinology Associates"
            }, 
            "investigator": {
                "last_name": "Murray Gordon, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE 3, MULTICENTER STUDY DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF A LONG ACTING HGH PRODUCT (MOD-4023) IN ADULT SUBJECTS WITH GROWTH HORMONE DEFICIENCY", 
        "overall_contact": {
            "email": "eyal@prolor-biotech.com", 
            "last_name": "Eyal Fima, Ph.D.", 
            "phone": "+972-8-9543103"
        }, 
        "overall_contact_backup": {
            "email": "leanne@prolor-biotech.com", 
            "last_name": "Leanne Amitzi, M.Sc.", 
            "phone": "+972-8-9543129"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in trunk FM, expressed in kilograms measured with DXA, from baseline to week 26", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "AEs, abnormal laboratory results (including glucose metabolism), immunogenicity, ECG.", 
                "measure": "Safety measures", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in total FM, expressed in kilograms, measured with DXA, from baseline to 26 and 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change in lean body mass, expressed in kilograms measured with DXA, from baseline to 26 and 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change in trunk FM, expressed in kilograms measured with DXA, from baseline to 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change in trunk FM, expressed as % change from baseline, measured with DXA, from baseline to 26 and 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Prolor Biotech, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prolor Biotech, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}